Scribe Therapeutics Inc. (SCTX)
NASDAQ: SCTX · Real-Time Price · USD
30.25
-1.09 (-3.48%)
Sep 9, 2026, 11:39 AM EDT - Market open
Scribe Therapeutics Revenue
Scribe Therapeutics had revenue of $1.92M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $33.30M. In the year 2025, Scribe Therapeutics had annual revenue of $51.17M with 86.68% growth.
Revenue (ttm)
$33.30M
Revenue Growth
+86.68%
P/S Ratio
17.82
Revenue / Employee
$374,180
Employees
89
Market Cap
572.68M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.17M | 23.76M | 86.68% |
| Dec 31, 2024 | 27.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
SCTX News
- 6 days ago - Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72) - TheFly
- 6 days ago - Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 days ago - Scribe Therapeutics Earnings release: Q2 2026 - Filings
- 6 days ago - Scribe Therapeutics Quarterly report: Q2 2026 - Filings
- 7 days ago - Scribe Therapeutics Slides: Investor presentation - Filings
- 8 days ago - Scribe Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 9 days ago - Scribe Therapeutics initiated with a Buy at H.C. Wainwright - TheFly
- 21 days ago - Leerink starts Scribe Therapeutics at Outperform on X-editor platform - TheFly